Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-01-18
2003-09-23
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06624170
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method for treating cancer in mammals, more particularly, to a method for treating malignant tumors such as lung, breast, stomach, pancreatic, prostate, bladder, osteosarcoma and ovary carcinomas and malignant melanomas.
BACKGROUND OF THE INVENTION
20(S)-camptothecin (CPT), a plant alkaloid, was found to have anticancer activity in 1966 (Wall, M., Wani, M. C., Cooke, C. E., Palmer, K. H., McPhail, A. T. and Slim, G. A. “Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from
Camptotheca acuminata”, J. Am. Chem. Soc.
88: 3888-3890, 1966).
During the sixties and seventies the sodium salt of CPT was derived from CPT, and clinical trials of this chemically altered CPT were carried out and then abandoned because of the high toxicity and low potency of this compound (Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T. and Block, J. B. “Preliminary pharmacological and clinical evaluation of camptothecin sodium salt (NSC 100880)”,
Cancer Chemother. Rep.
54: 461-470; 1979; Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. N. and Selawry, D. S. “Phase I clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies.”
Cancer Chemother. Rep.
56: 515-521; 1972; Gottlieb, J. A. and Luce, J. K. “Treatment of malignant melanoma with camptothecin (NSC 100880).”
Cancer Chemother. Rep.
56: 103-105; 1972; and Moertel, C. G., Schutt, A. J., Reitemeier, R. J. and Hahn, R. G. “Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer.”
Cancer Chemother. Rep.
56: 95-101; 1972. All these trials were conducted using the hydrosoluble, sodium salt derivative of CPT (CPT Na+), which was administered via i.v. The research of the present inventors has fully confirmed the ineffectiveness and the toxicity of CPT Na+.
Experiments have demonstrated that the non-water soluble CPT is nontoxic and highly effective as an anticancer agent. Furthermore, the present inventors have demonstrated that the intramuscular and oral administration provide unexpectedly better results than the intravenous administration.
Drug therapies have been evaluated with respect to treating human cancer, e.g., human cancer xenograft lines. Human tumors are serially heterotransplanted into immunodeficient, so-called “nude” mice, and the mice then tested for their responsiveness to a specific drug. (Giovanella, B. C., et al.,
Cancer
52(7):1146 (1983)). The data obtained in these studies strongly support the validity of heterotransplanted human tumors into immunodeficient mammals, such as nude mice, as a predictive model for testing the effectiveness of anticancer agents.
It was determined that 9-Amino-20(S)-Camptothecin (9AC) and 10,11-Methylendioxy-20(S)-Camptothecin (10,11MD) are capable of having high anticancer activity against human colon cancer xenografts (Giovanella, B. C., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. “Highly effective topoisomerase-I targeted chemotherapy of human colon cancer in xenografts.”
Science
246: 1046-1048; 1989). After this finding, the present inventors extended these studies to other human cancers growing as xenografts in nude mice as well as conducted studies on the administration of CPT and its derivatives. It is important to note that the fundamental difference between the chemical used by the present invention (CPT) and the one used ineffectively and with high attendant toxicity in the past (CPT Na+) is that CPT is water-insoluble and CPT Na+ is water-soluble.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a novel method for treating cancers in mammals.
Additional objects and advantages of the present invention will be set forth in part in the description which follows, and in part will be apparent from the description, or may be learned by practice of the present invention. The objects and advantages of the present invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
To achieve the objects and in accordance with the purpose of the present invention, as embodied and broadly described herein, the present invention relates to a method for treating malignant tumors in a mammal which comprises administering intramuscularly, orally or transdermally an effective amount of a water-insoluble 20(S)-Camptothecin (CPT) with the closed-lactone ring intact or a derivative thereof or a mixture thereof.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present invention, as claimed.
REFERENCES:
patent: 3894029 (1975-07-01), Winterfeldt et al.
patent: 4031098 (1977-06-01), Sugasawa
patent: 4357422 (1982-11-01), Giard et al.
patent: 4399276 (1983-08-01), Miyasaka et al.
patent: 4399282 (1983-08-01), Miyasaka et al.
patent: 4473692 (1984-09-01), Miyasaka et al.
patent: 4513138 (1985-04-01), Miyasaka et al.
patent: 4545880 (1985-10-01), Miyasaka et al.
patent: 4604463 (1986-08-01), Miyasaka et al.
patent: RE32518 (1987-10-01), Miyasaka et al.
patent: 4774236 (1988-09-01), Cook et al.
patent: 4867978 (1989-09-01), Gold
patent: 4874779 (1989-10-01), Senter
patent: 4894456 (1990-01-01), Wall et al.
patent: 4904768 (1990-02-01), Saulnier et al.
patent: 4914205 (1990-04-01), Sawada et al.
patent: 4939255 (1990-07-01), Tagawa et al.
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 4981968 (1991-01-01), Wall et al.
patent: 5004758 (1991-04-01), Boehm et al.
patent: 5041424 (1991-08-01), Saulnier et al.
patent: 5049668 (1991-09-01), Wall et al.
patent: 5053512 (1991-10-01), Wani et al.
patent: 5061795 (1991-10-01), Tagawa et al.
patent: 5061800 (1991-10-01), Yaegashi et al.
patent: 5064823 (1991-11-01), Lee et al.
patent: 5106742 (1992-04-01), Wall et al.
patent: 5122526 (1992-06-01), Wall et al.
patent: 5122606 (1992-06-01), Wani et al.
patent: 5126351 (1992-06-01), Luzzio et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5155225 (1992-10-01), Fortunak et al.
patent: 5162532 (1992-11-01), Comins et al.
patent: 5180722 (1993-01-01), Wall et al.
patent: 5225404 (1993-07-01), Giovannella et al.
patent: 5552154 (1996-09-01), Giovanella et al.
patent: 5652244 (1997-07-01), Giovanella et al.
patent: 5889017 (1999-03-01), Giovanella et al.
patent: 6080751 (2000-06-01), Stehlin et al.
patent: 6166029 (2000-12-01), Giovanella et al.
patent: 0 074 256 (1983-03-01), None
patent: 0 220 601 (1987-05-01), None
patent: 0 418 099 (1991-03-01), None
patent: 0 540 099 (1993-05-01), None
patent: 61-50985 (1983-03-01), None
patent: 59-5188 (1984-01-01), None
patent: 59-46284 (1984-03-01), None
patent: 59-51287 (1984-03-01), None
patent: 59-51288 (1984-03-01), None
patent: 59-51289 (1984-03-01), None
patent: 59-501288 (1984-03-01), None
patent: 61-85319 (1986-04-01), None
patent: 61-85389 (1986-04-01), None
patent: WO 91 05556 (1991-05-01), None
patent: WO 91/16904 (1991-11-01), None
patent: WO 93/09782 (1993-05-01), None
patent: WO 93/11770 (1993-06-01), None
Giovanella, et al., “Protocols for the Treatment of Huma Tumor Xenografts with Camptothecin”,The Annals of the New York Academy of Sciences, 803:181-187 (Dec. 13, 1996).
Natelson, et al., “Phase I Clinical and Pharmacological Studies of 20-(S)-Camptothecin and 20-(S)-9-Nitrocamptothecin as Anticancer Agents”,The Annals of the New York Academy of Sciences, 803:181-187 (Dec. 13, 1996).
1992 AACR Abstract Form “Pharmacokinetics of Tritum Labeled Camptothecin in Nude Mice,” Smith, P.L. et al.
1992 AACR Abstract Form, “Growth Inhibition of Human Cancer Metasteses in the Xenograft Model by Camptothecin [NSC 946000], 9-amino-(NSC 60371) and 9-nitrocamptothecin,” Potmesil, M.
Giovanella et al., Cancer Research, vol. 51, pp. 3052-3055, Jun. 1, 1991.
Kharbanda et al., Cancer Research, vol. 51, pp. 6636-6642, Dec. 15, 1991.
The Alkaloids, vol. XX
Giovanella Beppino C.
Hinz Hellmuth R.
Kozielski Anthony J.
Stehlin John S.
Goldberg Jerome D.
Kilyk & Bowersox P.L.L.C.
The Stehlin Foundation For Cancer Research
LandOfFree
Method for treating cancer with water-insoluble... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cancer with water-insoluble..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cancer with water-insoluble... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3060733